Nu Skin Enterprises, Inc. (NUS) is a global enterprise dedicated to the creation and worldwide distribution of beauty and wellness solutions. The company's diverse product offerings encompass advanced skincare systems, such as the ageLOC Spa and ageLOC Transformation age-defying lines, innovative devices like the ageLOC LumiSpa for comprehensive skin treatment and cleansing, and the ageLOC Boost, alongside various other cosmetic and personal care items. In the realm of health and nutrition, Nu Skin provides a comprehensive array of dietary and weight management products. This includes ageLOC Youth, LifePak, and ageLOC Meta nutritional supplements, in addition to ageLOC TR90 programs designed for weight control and body contouring, Beauty Focus Collagen+ skin care supplements, and other related weight management aids. The organization also significantly invests in research and development, particularly for its skincare and nutritional supplement portfolios. Nu Skin operates a network of retail stores and customer service centers exclusively within Mainland China. Its extensive product lines are marketed under its proprietary brands, which include Nu Skin, Pharmanex, and ageLOC. These products reach consumers through multiple sales channels, including direct-to-consumer interactions, an extensive network of independent distributors, and its dedicated e-commerce platform. Nu Skin Enterprises, Inc. was established in 1984 and maintains its corporate headquarters in Provo, Utah.
Imminent Q3 2026 earnings release on Nov 5 is the dominant near-term catalyst, with elevated downside risk given prior guidance cut and continued revenue decline.
Nu Skin will report Q3 2026 results after market close on Nov 5, with a conference call at 5 p.m. ET. Given the August guidance cut (FY26 revenue $1.28B-$1.35B, adjusted EPS $0.70-$0.90) and Q3 guidance of $310M-$340M revenue and $0.10-$0.20 adjusted EPS, results and any further guidance revision are likely to drive sharp near-term price movement.
Nu Skin Enterprises Press ReleaseOn Aug 10, Nu Skin cut FY26 revenue guidance to $1.28B-$1.35B from $1.35B-$1.50B and adjusted EPS to $0.70-$0.90 from $0.80-$1.20, and shifted India launch timing to 1H27. The reduced outlook and continued double-digit revenue decline keep execution risk elevated into the Q3 print.
Nu Skin Enterprises Press ReleaseQ2 2026 GAAP EPS was $(5.14) versus $0.43 a year ago, driven by a $78.9M non-cash goodwill impairment and a $167.5M deferred-tax valuation allowance, producing a $249.8M net loss. The charges raise balance-sheet and earnings-quality concerns that could weigh on sentiment ahead of Q3.
Simply Wall StNu Skin was ranked the world's No. 1 beauty and wellness device company by Euromonitor for a third consecutive year, and Prysm iO has surpassed 39,000 devices placed with a year-end target of 50,000-60,000. Progress on this key growth initiative could support sentiment if confirmed at the Q3 call.
Nu Skin Enterprises Company News